ULTRASTRUCTURAL BASES OF THE REORGANIZATION OF THE MYOCARDIUM IN CHRONIC ANTHRACYCLINE CARDIOMYOPATHY IN THE EXPERIMENT

Abstract

Electron-microscopic method was used to study the mechanisms of ultrastructural reorganization of the myocardium and blood vessels of the microvascular bed of the heart muscle from rats (n=30) at different time intervals after modeling of chronic anthracycline cardiomyopathy. The signs of progressive destructive changes in the myocardium, leading to the death of cardiomyocytes and the diturbances of its functional activity were demonstrated. The vessels of the microvascular bed of the myocardium underwent irreversible structural changes and were compressed by the newly formed collagen fibers in the myocardial interstitium. Exclusion of the blood vessels of the heart muscle from the blood flow is a likely cause of myocardial ischemia and congestive heart failure development.

Keywords

myocardium / cardiomyocyte / endotheliocyte / anthracyclines / doxorubicin

References

[1] Боголепов Н. Н. Методы электронно-микроскопического исследования мозга. М., 1976.

[2] Лушникова Е. Л., Непомнящих Л. М., Розенберг В. Д. Морфологические и молекулярно-генетические основы дилатационной кардиомиопатии. М.: Изд-во РАМН, 2004.

[3] Технический кодекс установившейся практики. ТКП 125-2008 (02040). Надлежащая лабораторная практика. Постановление Министерства здравоохранения Респ. Беларусь № 56 от 28 марта 2008 г.

[4] Akao M., O’Rourke B., Kusuoka H. Differential actions of cardioprotective agents on the mitochondrial death pathway // Circ. Res. 2003. Vol. 7, № 92(2). P. 195-202.

[5] Bertinchant J. P., Larue C., Pernel I. et al. Release kinetics of serum cardiac troponin I in ischemic myocardial injury // Clin. Biochem. 1996. Vol. 29. P. 587-594.

[6] Boucek R. J.J, Miracle A., Anderson M. Persistant effects of doxo rubicin on cardiac gene expression // J. Mol. Cell Cardiol. 1999. Vol. 31. P. 1435-1446.

[7] European Convention for the Protection of Vertebrate Animals Used for Experimentation and other Scientific Purposes, N 123 of 18 March 1986; Protocol of Amendment to the European Convention for the Protection of Vertebrate Animals used for Experimental and other Scientific Purposes, Strasbourg, 22 June 1998.

[8] Gille L., Nohl H. Analyses of the molecular mechanism of adriamycin-induced cardiotoxicity // Free Radic. Biol. Med. 1997. Vol. 23, Suppl. 5. P. 775-782.

[9] Grenier M. A., Lipshultz S. E. Epidemiology of anthracycline cardiotoxicity in children and adults // Semin. Oncol. 1998. Vol. 25, Suppl. 10. P. 72-85.

[10] Jensen B. V., Skovsgaard T., Nielsen S. L. Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients // Ann. Oncol. 2002. Vol. 13. P. 699-709.

[11] Kumar S., Marfatia R., Tannenbaum S. et al. Doxorubicin-induced cardiomyopathy 17 years after chemotherapy // Tex. Heart Inst. J. 2012. Vol. 39, № 3. P. 424-427.

[12] L’Ecuyer T., Sanjeev S., Thomas R. et al. DNA damage is an early event in doxorubicin-induced cardiac myocyte death // Am. J. Physiol. Heart Circ. Physiol. 2006. Vol. 291, № 3. P. 1273- 1280.

[13] Sacco G., Giampietro R., Salvatorelli E. et al. Chronic cardiotoxicity of anticancer anthracyclines in the rat: role of secondary metabolites and reduced toxicity by a novel anthracycline with impaired metabolite formation and reactivity // Br. J. Pharmacol. 2003. Vol. 139, № 3. P. 641-651.

[14] Takemura G., Fujiwara H. Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management // Prog. Cardiovasc. Dis. 2007. Vol. 49. P. 330-352.

[15] Yamashita J, Ogawa M, Nomura K. Plasma endothelin-1 and doxorubicin cardiotoxicity // N. Engl. J. Med. 1994. Vol. 331. P. 1528-1529.

[16] Yeh E. T., Bickford C. L. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis and management // J. Am. Coll. Cardiol. 2009. Vol. 16, № 53. P. 2231-2247.

[17] Zhou S., Starkov A., Froberg M. K. et al. Cumulative and irreversible cardiac mitochondrial dysfunction induced by doxorubicin // Cancer Res. 2001. Vol. 61. P. 771-777.

RIGHTS & PERMISSIONS

Eco-Vector